Company Description
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.
The company’s lead medical device NELL-1/DBM, an osteopromotive recombinant protein that provides target-specific control over bone regeneration.
It also develops NELL-1/DBM fusion device used in lumbar spinal fusion. The company’s NELL-1 platform technology used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine.
The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications.
Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Jeffrey Frelick |
Contact Details
Address: 2 Burlington Woods Drive, Suite 100 Burlington, Massachusetts 01803 United States | |
| Phone | 781 552 4452 |
| Website | bonebiologics.com |
Stock Details
| Ticker Symbol | BBLG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419554 |
| CUSIP Number | 098070303 |
| ISIN Number | US0980705018 |
| Employer ID | 42-1743430 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey Frelick | Chief Executive Officer and President |
| Deina H. Walsh CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 30, 2025 | 8-K | Current Report |
| Jun 30, 2025 | 424B4 | Prospectus |
| Jun 27, 2025 | EFFECT | Notice of Effectiveness |
| Jun 26, 2025 | 8-K | Current Report |
| Jun 24, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 24, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 6, 2025 | 8-K | Current Report |
| May 30, 2025 | 8-K | Current Report |
| May 12, 2025 | 10-Q | Quarterly Report |
| Apr 23, 2025 | ARS | Filing |